Evaluation of the safety of high-dose Lactobacillus gasseri CP2305 supplementation in healthy adults: A randomized, double-blind, placebo-controlled study
The results of this study demonstrate that no safety concerns were identified in the physical examinations, hematology, blood biochemistry, urinalysis, or subjective symptoms. These findings support the safety of <i>L. gasseri</i> CP2305 tablets even at high-dose intake (1.0 ×10 ¹¹ cells/day).
Authors
- Kazuhiko Takano
- Hajime Fuchida
- Tatsuhiko Hirota
- Daisuke Sawada
- Hiroki Miyashita
- Koji Mochizuki
Institutions
- Hokuyukai Neurology Hospital (JP)
- Sapporo Higashi Tokushukai Hospital (JP)
- Asahi Breweries (Japan) (JP)
- Sapporo Science Center (JP)
Publication Details
- Journal
- Toxicology Reports
- Published
- 2026-02-13
- DOI
- https://doi.org/10.1016/j.toxrep.2026.102222
- Primary Topic
- Probiotics and Fermented Foods
- Type
- article
- Field-Weighted Citation Impact
- 0.00